Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

Liberman, Uri; Weiss, Stuart; Bröll, Johann; Minne, H. W.; Quan, Hui; Bell, Norman H.; Rodríguez-Portales, José A.; Downs, Robert W.; Dequeker, Jan; Favus, Murray J.; Seeman, Ego; Recker, Robert R.; Capizzi, Thomas; Santora, Arthur C.; Lombardi, Antonio; Shah, Raksha V.; Hirsch, Laurence; Karpf, David

doi:10.1056/nejm199511303332201

Cited by 2,129 publications

(1,267 citation statements)

References 30 publications

Supporting

Mentioning

1,138

Contrasting

Unclassified

Order By: Relevance

“…Bisphosphonates are today's worldwide leading medication [7][8][9][10][11][12][13][14][15][16] and are recommended as first-line treatments for osteoporosis [1,2,17,18]. Two chemically distinct groups of bisphosphonates exist: Simple non-nitrogen-containing bisphosphonates (Non-N-BP's, e.g., Etidronate) and nitrogen-containing bisphosphonates (N-BP´s) e.g., Ibandronate, Alendronate, Zoledronate and Risedronate).…”

Section: Bisphosphonates Are the Most Common Therapy For Osteoporosismentioning

confidence: 99%

“…There exists some evidence that branded Risedronate might be a slightly better suitable alternative bisphosphonate drug for gastrointestinal sensitive patients compared to original branded or generic Alendronate [7][8][9]32,33,[39][40][41][42][43][44][45][46]. Two recent studies have shown differences in tablets properties that might explain different rates of adverse events.…”

Section: Lower Bioavailability and Higher Rate Of Adverse Events Due mentioning

confidence: 99%

See 1 more Smart Citation

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Ringe

Möller

2009

Rheumatol Int

View full text Add to dashboard Cite

Section: Bisphosphonates Are the Most Common Therapy For Osteoporosismentioning

confidence: 99%

Section: Lower Bioavailability and Higher Rate Of Adverse Events Due mentioning

confidence: 99%

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Ringe

Möller

2009

Rheumatol Int

View full text Add to dashboard Cite

“…However, the changes in BMD explain only a fraction of the observed fracture risk reduction [5][6][7]. These observations suggest that anti-resorptive agents improve bone strength by decreasing bone turnover and by increasing intrinsic material properties of bone rather than simply affecting bone mass.…”

Section: Introductionmentioning

confidence: 97%

The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength

Yao

Cheng

Koester

et al. 2007

Bone

View full text Add to dashboard Cite

The treatment of osteoporotic women with bisphosphonates significantly reduces the incidence of bone fractures to a degree greater than can be explained by an increase in bone mineral density. In this Study, 18 month Fischer 344 rats were ovariectomized and treated with a single dose of risedronate (intravenous, iv, 500μg), zoledronic acid (iv, 100μg) or continuous raloxifene (2mg/ kg, po., 3x/wk). High resolution microCT was used to measure lumbar vertebral bone microarchitecture, the degree of bone mineralization (DBM) and the distribution of mineral. Small angle x-ray scattering was used to investigate mineral crystallinity. We found prolonged estrogen deficiency, reduced trabecular bone volume, and increased micro architecture bone compression strength. lowered the degree of mineralization. Treatment with resorptive agents (bisphosphonates > raloxifene) prevented the loss of mineralization, trabecular bone volume and bone compression strength. Crystal size was not changed with OVX or with anti-resorptive treatments. In conclusion, in the aged estrogen deficient rat model, single intravenous doses of two bisphosphonates were effective in maintaining the compressive bone strength for 180 days by reducing bone turnover, and maintaining the DBM to a greater degree than with raloxifene.

show abstract

“…It reduced the risk of fracture by about 50% in patients with prevalent lowtrauma fracture [45]. Subsequently, three more BPs have been approved: risedronate, ibandronate, and zoledronic acid.…”

Section: Bisphosphonatesmentioning

confidence: 99%

The Effect of Antiresorptives on Bone Quality

Recker

Armas

2011

Clinical Orthopaedics &Amp; Related Research

Self Cite

View full text Add to dashboard Cite

Background Currently, antiresorptive therapy in the treatment and prevention of osteoporosis includes bisphosphonates, estrogen replacement, selective estrogen receptor modulators (raloxifene), and denosumab (a human antibody that inactivates RANKL). The original paradigm driving the development of antiresorptive therapy was that inhibition of bone resorption would allow bone formation to continue and correct the defect. However, it is now clear increases in bone density account for little of the antifracture effect of these treatments. Questions/purposes We examined the antifracture benefit of antiresorptives deriving from bone quality changes. Methods We searched the archive of nearly 30,000 articles accumulated over more than 40 years in our research center library using a software program (Refman TM ). Approximately 250 publications were identified in locating the 69 cited here.

show abstract

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

Abstract: Daily treatment with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebral deformities, and height loss in postmenopausal women with osteoporosis.

Cited by 2,129 publications

References 30 publications

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis

The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength

The Effect of Antiresorptives on Bone Quality

Contact Info

Product

Resources

About